The integration of artificial intelligence (AI) into clinical trial protocol digitalization is transforming key aspects of drug development. By applying analytical and predictive AI, there is the potential to design smarter, more efficient protocols, ensuring greater precision in endpoint definition, improved compliance, and reduced trial timelines. This article explores some of the applications AI… Continue reading AI-Driven Protocol Digitalization: Reshaping Clinical Research
Category: Methodology
Digital Twins in Healthcare: Unlocking Potential and Overcoming Challenges
The concept of digital twins has gained significant attention in recent years, revolutionizing industries such as manufacturing, urban planning, and increasingly, and healthcare. A digital twin is a virtual replica of a physical object, system, or process, enabling real-time monitoring, simulation, and analysis. By creating a digital version of something in the real world, industries… Continue reading Digital Twins in Healthcare: Unlocking Potential and Overcoming Challenges
The Evolving Integration of NGS Data into EMRs: Transforming Clinical Research and Precision Medicine
Next-Generation Sequencing (NGS) is a technology that allows the rapid sequencing of entire genomes, targeted regions, or specific sets of genes. It represents a significant advancement that enables the parallel sequencing of millions of DNA fragments simultaneously. NGS can be used for a variety of applications, including whole-genome sequencing (WGS), whole-exome sequencing (WES), targeted gene… Continue reading The Evolving Integration of NGS Data into EMRs: Transforming Clinical Research and Precision Medicine
Leveraging Natural History of Disease Studies for Integrated Evidence Generation Plans and Regulatory Success
Natural history of disease studies are intended to track the course of a disease by identifying demographic, genetic, environmental, and other variables (e.g., treatments, concomitant medications) that correlate with the disease’s development and outcomes. Natural history of disease studies play a crucial role in integrated evidence generation plans, especially for rare diseases and conditions where… Continue reading Leveraging Natural History of Disease Studies for Integrated Evidence Generation Plans and Regulatory Success
RWD for EMA Regulatory Submissions: Differences in Use for Pre- vs. Post-Approval
Real‐world evidence (RWE) has an increasing role in both pre-, and post- approval applications to support the authorization of new medicines and indications, or to address post-marketing safety concerns. Therefore, the use of Real-World Data (RWD) in regulatory processes at the European Medicines Agency (EMA) varies depending on whether it is being used for… Continue reading RWD for EMA Regulatory Submissions: Differences in Use for Pre- vs. Post-Approval